Physician profile
Julia M Feudo
NPI 1679503551
$2,001.35
in general payments reported to CMS, 2019-2025
28 companies · $240 in 2025
The $240 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $162 · 2021: $253 · 2022: $267 · 2023: $311 · 2024: $314 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $366.93 | 2019-2025 | |
| Qiagen, LLC | $199.88 | 2019 | |
| Glaxosmithkline, LLC. | $185.04 | 2020-2023 | Bexsero |
| Supernus Pharmaceuticals, INC. | $179.64 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $166.65 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $92.83 | 2020-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Phadia US INC. | $87.15 | 2019-2025 | Immunocap |
| Cranial Technologies, INC | $86.15 | 2023-2025 | Doc Band |
| Astrazeneca Pharmaceuticals Lp | $66.11 | 2021-2022 | |
| Seqirus USA INC | $55.37 | 2022-2023 | Flucelvax Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $48.56 | 2024-2025 | Zoryve |
| Abbvie INC. | $41.51 | 2020 | |
| Sanofi Pasteur INC. | $38.92 | 2019-2024 | |
| Hologic Sales and Service, LLC | $37.93 | 2023 | Aptima, Third Wave |
| Sobi, INC | $37.41 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $36.80 | 2022 | |
| Tris Pharma INC | $33.76 | 2020-2021 | |
| Kaleo, INC. | $30.90 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $24.53 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.75 | 2019 | |
| Acadia Pharmaceuticals INC | $22.71 | 2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $22.59 | 2025 | |
| Kyowa Kirin, INC. | $22.37 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $20.02 | 2021 | |
| Shire North American Group INC | $19.68 | 2019 | |
| Aimmune Therapeutics, INC. | $18.92 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.91 | 2019 | |
| Genzyme Corporation | $16.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Feudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.